MONTREAL, June 13 /CNW/ - ConjuChem Biotechnologies Inc. (TSX: CJB - News) announced today that data relating to its proprietary PC-DAC(TM):Exendin-4 compound for the treatment of Type 2 diabetes was presented at the 66th Scientific Sessions of the American Diabetes Association (ADA) held June 9-13, 2006 in Washington, D.C. The ADA’s annual Scientific Sessions meeting is one of the largest gatherings of health care professionals involved in diabetes research and the delivery of diabetes care.
